STAAR Surgical - STAA Stock Forecast, Price & News

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for STAAR Surgical in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" STAA shares.
View STAA analyst ratings or view top-rated stocks.

5 equities research analysts have issued 1 year price targets for STAAR Surgical's stock. Their STAA share price forecasts range from $89.00 to $125.00. On average, they anticipate the company's share price to reach $106.83 in the next year. This suggests a possible upside of 51.4% from the stock's current price.
View analysts price targets for STAA or view top-rated stocks among Wall Street analysts.

STAAR Surgical's stock was trading at $91.30 on January 1st, 2022. Since then, STAA shares have decreased by 22.7% and is now trading at $70.55.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our STAA earnings forecast.

STAAR Surgical (NASDAQ:STAA) issued its quarterly earnings results on Wednesday, August, 10th. The medical instruments supplier reported $0.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.18 by $0.12. The medical instruments supplier had revenue of $81.10 million for the quarter, compared to analysts' expectations of $80.12 million. STAAR Surgical had a net margin of 12.84% and a trailing twelve-month return on equity of 13.99%. The business's quarterly revenue was up 30.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.19 earnings per share.

STAAR Surgical issued an update on its FY 2022 earnings guidance on Friday, September, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $295.00 million-$295.00 million, compared to the consensus revenue estimate of $295.67 million.

6 employees have rated STAAR Surgical Chief Executive Officer Caren Mason on Glassdoor.com. Caren Mason has an approval rating of 68% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other STAAR Surgical investors own include Tesla (TSLA), NVIDIA (NVDA), PayPal (PYPL), Walt Disney (DIS), CrowdStrike (CRWD), DocuSign (DOCU), Shopify (SHOP), Trade Desk (TTD), Teladoc Health (TDOC) and Roku (ROKU).

STAAR Surgical trades on the NASDAQ under the ticker symbol "STAA."

Shares of STAA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of STAA stock can currently be purchased for approximately $70.55.

STAAR Surgical (NASDAQ:STAA) has a market capitalization of $3.39 billion and generates $230.47 million in revenue each year. The medical instruments supplier earns $24.50 million in net income (profit) each year or $0.67 on an earnings per share basis.

The company employs 692 workers across the globe.

STAAR Surgical's mailing address is 25651 ATLANTIC OCEAN DRIVE, LAKE FOREST CA, 92630. The official website for the company is www.staar.com. The medical instruments supplier can be reached via phone at (626) 303-7902, via email at bmoore@staar.com, or via fax at 626-303-2962.